Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects

被引：0
|
作者：
Shah, Jaymin [1 ]
Pozo, Katherine [2 ]
Scott, Deborah [2 ]
Lin, WeiQi [2 ]
机构：
[1] Durect, Clin Pharmacol, Cupertino, CA USA
[2] Durect, Clin, Cupertino, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-668
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [1] Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
    Hassanein, Tarek
    McClain, Craig J.
    Vatsalya, Vatsalya
    Stein, Lance L.
    Flamm, Steven L.
    Martin, Paul
    Cave, Matthew C.
    Mitchell, Mack
    Barton, Bruce
    Nagy, Laura
    Szabo, Gyongyi
    McCullough, Arthur
    Dasarathy, Srinivasin
    Shah, Jaymin
    Blevins, Christina
    Scott, Deborah
    Krebs, William
    Brown, James E.
    Lin, WeiQi
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (01): : 107 - 115
  • [2] SAFETY AND EFFICACY SIGNALS OF 4-WEEK ORAL DUR-928 IN NASH SUBJECTS
    Lawitz, Eric J.
    Hassanein, Tarek
    Borg, Brian
    Waters, Michael
    Mille, Gwenaelle
    Scott, Deborah
    Miksztal, Andy
    Culwell, John
    Ellis, Dave
    Brown, Jim
    Lin, WeiQi
    [J]. HEPATOLOGY, 2020, 72 : 1031 - 1032
  • [3] PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION
    Noel, Benoit
    Vargas, Dawn
    Georges-Coty, Anne
    Roudot, Alice
    Roux, Olivier
    Magrez, David
    Wyatt, David
    Birman, Pascal
    Addy, Carol
    [J]. HEPATOLOGY, 2021, 74 : 772A - 773A
  • [4] Efficacy Signals Of 4-Week Oral DUR-928 in NASH Subjects
    Lawitz, Eric
    Hassanein, Tarek
    Denham, Douglas
    Waters, Michael
    Borg, Brian
    Mille, Gwenaelle
    Scott, Deborah
    Miksztal, Andy
    Culwell, John
    Ellis, Dave
    Brown, James
    Lin, Weiqi
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S618 - S618
  • [5] Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis- A phase 1b study
    Kemp, W.
    Shah, J.
    Ellis, D.
    Brown, J.
    Theeuwes, F.
    Lin, W.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S596 - S596
  • [6] Pharmacokinetics of DUR-928 in alcoholic hepatitis patients - a phase 2a study
    Shah, Jaymin
    Blevins, Christina
    Scott, Deborah
    Lin, WeiQi
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S180 - S181
  • [7] SAFETY AND EFFICACY OF DUR-928: A POTENTIAL NEW THERAPY FOR ACUTE ALCOHOLIC HEPATITIS
    Hassanein, Tarek
    Stein, Lance L.
    Flamm, Steven L.
    Martin, Paul
    Cave, Matthew C.
    Blevins, Christina
    Scott, Deborah
    Krebs, William
    Lin, WeiQi
    [J]. HEPATOLOGY, 2019, 70 (06) : 1483A - 1484A
  • [8] Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
    Borin, Marie T.
    Lo, Arthur
    Barnes, Chris N.
    Pendyala, Srikanth
    Bourdet, David L.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 2305 - 2318
  • [9] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [10] DUR-928 THERAPY FOR ACUTE ALCOHOLIC HEPATITIS: A PILOT STUDY
    McClain, Craig J.
    Vatsalya, Vatsalya
    Hassanein, Tarek I.
    Stein, Lance L.
    Flamm, Steven L.
    Martin, Paul
    Cave, Matthew C.
    Lin, WeiQi
    [J]. HEPATOLOGY, 2019, 70 : 834A - 835A
12345